Associated tags: Therapy, Drug resistance, Research, Science, Doctor of Philosophy, Clinical Trials, Oncology, Patient, Health, Pharmaceutical, Biotechnology, FDA, Pharmaceutical industry, Clinical trial, Pharmacokinetics, Cancer, University, EGFR, CBP, Safety
Locations: SWITZERLAND, EUROPE, MINNESOTA, SAN FRANCISCO, KRAS, AR, DARTMOUTH, OREGON
Oncology,
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Executive,
SAB,
Publication,
Professor,
Abstract,
Drug resistance,
Vanderbilt University,
Internal medicine,
Roche,
Genentech,
Doctor of Philosophy,
Rush Medical College,
Mirati Therapeutics,
Mirati,
Indiana University,
Senior,
CBP,
Therapy,
Assistant,
Drug development,
Bristol Myers Squibb,
Associate,
Division,
Pharmaceutical industry TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Alan Sandler, M.D., to its Scientific Advisory Board (SAB).
Key Points:
- TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Alan Sandler, M.D., to its Scientific Advisory Board (SAB).
- The company’s lead candidate, TT125-802, is a small molecule CBP/p300 bromodomain inhibitor currently advancing through a Phase 1 clinical trial.
- “Alan brings extensive experience in drug development, including clinical development experience with one of the leading KRAS inhibitors,” said Stefanie Flückiger-Mangual, PhD, Co-founder and Chief Executive Officer of TOLREMO.
- The team has discovered an exciting pivotal mechanism that governs critical transcriptional resistance pathways,” said Alan Sandler, M.D., Scientific Advisory Board member at TOLREMO.
Research,
Clinical Trials,
Other Health,
Biotechnology,
General Health,
Pharmaceutical,
Health,
Science,
Oncology,
Other Science,
Boston Scientific,
Werewolf,
Growth,
Genentech,
Strategic management,
CFO,
Business,
Novartis,
Trustee,
Patient,
Chairperson,
Tuck School of Business,
CBO,
Sale,
Business development,
Acquisition,
University,
IPO,
Belharra,
Columbia Law School,
Doctor of Philosophy,
Senior,
MBA,
Clinical trial,
Therapy,
Guidant,
DePauw University,
Claremont McKenna College,
Drug resistance,
Celgene,
FDA,
Economics,
Corporation,
Management TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Jeff Jonker and Mike Sherman to its Board of Directors.
Key Points:
- TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Jeff Jonker and Mike Sherman to its Board of Directors.
- "We welcome Jeff and Mike to our Board of Directors as we make steady progress with TT125-802 in the clinic and continue our evolution into a clinical-stage company with expanding operations,” said Stefanie Flückiger-Mangual, PhD, Co-founder and Chief Executive Officer of TOLREMO.
- Jeff Jonker is an accomplished biotechnology executive with a wealth of experience across various leadership roles in the industry.
- Mike Sherman is a seasoned executive with over 30 years of life science experience and an established track record in biotech leadership.
Retrieved on:
Tuesday, November 28, 2023
Oncology,
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Translation,
Safety,
Food,
CBP,
IND,
Clinical trial,
Patient,
FDA,
Pharmacokinetics,
Drug resistance,
Investigational New Drug,
Therapy,
MD,
Cancer,
Doctor of Philosophy,
Biomarker,
EGFR,
Pharmaceutical industry TT125-802 is an orally available small molecule CBP/p300 bromodomain inhibitor designed to prevent non-genetic cancer drug resistance and thereby improve the response rates and durability of targeted cancer treatments.
Key Points:
- TT125-802 is an orally available small molecule CBP/p300 bromodomain inhibitor designed to prevent non-genetic cancer drug resistance and thereby improve the response rates and durability of targeted cancer treatments.
- In preclinical testing, the compound has demonstrated the ability to block critical transcriptional resistance pathways responsible for cancer’s earliest escape mechanisms to targeted therapies.
- "Initiating our Phase 1 clinical trial is an important corporate milestone for TOLREMO.
- “We are deeply committed to overcoming transcriptionally mediated cancer drug resistance for patient benefit, and this trial marks the start of an exciting new phase for the company.”
The Phase I dose-escalation study will enroll patients across a range of solid tumor indications.
Retrieved on:
Wednesday, September 20, 2023
Oncology,
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
KRAS,
Gilead Sciences,
SUGEN,
University,
Therapy,
CBP,
ARCH Venture Partners,
Stanford University,
Survival,
University of California, Davis,
Cancer,
Pharmacokinetics,
Coronavirus Scientific Advisory Board,
AG,
Drug resistance,
Patient,
EGFR,
Biology,
Health care,
FDA,
CHF,
AR,
Microbiology,
Safety,
Chair,
Pharmaceutical industry,
Doctor of Philosophy TOLREMO therapeutics AG (TOLREMO) today announced that it has completed its Series A financing, bringing the total amount raised to USD 39 million (CHF 34.1 million).
Key Points:
- TOLREMO therapeutics AG (TOLREMO) today announced that it has completed its Series A financing, bringing the total amount raised to USD 39 million (CHF 34.1 million).
- BioMedPartners AG led the round with participation from a new investor, Pierre Fabre Invest, as well as existing investors.
- Stepwise, TOLREMO will then advance to evaluating TT125-802 in combination with targeted therapies such as KRAS, EGFR or AR inhibitors in specific advanced solid tumor indications.
- In addition, Francesco Hofmann, PhD, Head of R&D for Medical Care at Pierre Fabre Laboratories, joined TOLREMO's Scientific Advisory Board.
